Article info
Review
Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development
- Dr Johann S de Bono, Cancer Research UK Centre for Cancer Therapeutics, The Institute for Cancer Research, The Royal Marsden NHS Foundation Trust, Downs Road Sutton, Surrey SM2 5PT, UK; jdebono{at}icr.ac.uk
Citation
Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development
Publication history
- Accepted April 13, 2008
- First published May 21, 2008.
Online issue publication
April 18, 2016
Article Versions
- Previous version (18 April 2016).
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2008 The BMJ Publishing Group Ltd and the Association of Clinical Pathologists